Signal Genetics, Inc. (NASDAQ: SGNL) is a commercial-stage molecular design company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company’s lead product is its MyPRS® test, which is a microarray-based gene expression profile assay designed to test the presence of various groups of genes that predict low or high level risk of early relapse in patients suffering from multiple myeloma. For more information, visit the company’s website at www.signalgenetics.com.
Signal Genetics (SGNL) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- MissionIRNewsBreaks – AI-Driven Energy Demands Highlight Strategic Value of Platinum Group Metals Ltd.’s (NYSE American: PLG) (TSX: PTM) Waterberg Project
- Brera Holdings PLC’s (NASDAQ: BREA) Becomes Second Multi-Club Owner in Italy’s Serie B, Signaling Rising Investment Opportunity
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
- MissionIRNewsBreaks – Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Reports Q1 Fiscal 2026 Net Income of $18.1 Million on $81.3 Million Revenue